Thus, taking together Trebananib’s novel immune regulatory properties and well-known vascular remodeling properties, the present study supports the combination of Ang1 and Ang2 inhibitors with cancer immunotherapy to potentiate antitumor activity. The gene discussed is ANGPT1; the disease is cancer.